2020
In vivo modeling of metastatic human high-grade serous ovarian cancer in mice
Kim O, Park EY, Klinkebiel DL, Pack SD, Shin YH, Abdullaev Z, Emerson RE, Coffey DM, Kwon SY, Creighton CJ, Kwon S, Chang EC, Chiang T, Yatsenko AN, Chien J, Cheon DJ, Yang-Hartwich Y, Nakshatri H, Nephew KP, Behringer RR, Fernández FM, Cho CH, Vanderhyden B, Drapkin R, Bast RC, Miller KD, Karpf AR, Kim J. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. PLOS Genetics 2020, 16: e1008808. PMID: 32497036, PMCID: PMC7297383, DOI: 10.1371/journal.pgen.1008808.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCell Line, TumorChromosomal InstabilityCystadenocarcinoma, SerousDEAD-box RNA HelicasesDisease Models, AnimalDNA RepairDrug Resistance, NeoplasmDrug Screening Assays, AntitumorFeasibility StudiesFemaleHumansMiceMice, KnockoutMutationNeoplasm GradingNeoplasm MetastasisOvarian NeoplasmsPeritoneal NeoplasmsPrimary Cell CulturePTEN PhosphohydrolaseRibonuclease IIITumor Suppressor Protein p53ConceptsHigh-grade serous carcinomaHuman HGSCHigh-grade serous ovarian cancerSerous ovarian cancerOvarian cancerPeritoneal metastasisHuman high-grade serous ovarian cancerMetastatic ovarian cancerOvarian cancer typesHuman cancer metastasisHuman cancer mortalityHemorrhagic ascitesClinical metastasisHistopathological similaritiesSerous carcinomaCancer mortalityFallopian tubeMurine modelPeritoneal cavityMouse modelPotential therapyMouse deathMetastasisCancer typesCancer metastasis
2019
p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT
Yang-Hartwich Y, Tedja R, Roberts C, Goodner-Bingham J, Cardenas C, Gurea M, Sumi NJ, Alvero AB, Glackin CA, Mor G. p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT. Molecular Cancer Research 2019, 17: molcanres.0238.2018. PMID: 30131448, PMCID: PMC6800184, DOI: 10.1158/1541-7786.mcr-18-0238.Peer-Reviewed Original ResearchConceptsEpithelial-mesenchymal transitionTwist1 degradationInvasive cancer phenotypeEMT-inducing transcription factorsAbility of p53Tumor suppressor geneTumor cell invasivenessWild-type p53Proteasomal degradationTranscription factorsTwist1 proteinSuppressor geneEpithelial phenotypeInhibits epithelial-mesenchymal transitionCancer phenotypeMolecular levelCell invasivenessCancer progressionCancer metastasisWt p53Twist1P53Metastatic processTumor progressionNew insights
2012
Constitutive proteasomal degradation of TWIST-1 in epithelial–ovarian cancer stem cells impacts differentiation and metastatic potential
Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, Yang Y, Chefetz-Menaker I, Nuti S, Rossi M, Silasi DA, Rutherford T, Mor G. Constitutive proteasomal degradation of TWIST-1 in epithelial–ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene 2012, 32: 39-49. PMID: 22349827, PMCID: PMC3703656, DOI: 10.1038/onc.2012.33.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell DifferentiationFemaleHumansHyaluronan ReceptorsMiceMyeloid Differentiation Factor 88Neoplasm MetastasisNeoplasms, Glandular and EpithelialNeoplastic Stem CellsNuclear ProteinsOvarian NeoplasmsProteasome Endopeptidase ComplexProteolysisTumor Cells, CulturedTwist-Related Protein 1ConceptsEpithelial ovarian cancer stem cellsEpithelial-mesenchymal transitionCancer stem cellsMesenchymal-epithelial transitionEOC stem cellsStem cellsTwist-1Differentiation processEpithelial cancer stem cellsSpecific cell typesEpithelial cancer cellsSpheroid-forming cellsProteasomal degradationEpithelial stem cellsMolecular mechanismsCell typesProgenitor cellsMetastasis processCancer metastasisCancer cellsDifferentiationMetastatic potentialAdditional signalsCellsCritical process